Abstract P005

Real-World Tolerability and Efficacy of BrECADD in Advanced-Stage Hodgkin Lymphoma: A Multicenter Brazilian Experience

Background: Since the introduction of the ABVD and BEACOPP regimen, Hodgkin Lymphoma (HL) has achieved high cure rates. Since then, new therapeutic regimens have been investigated aiming to improve outcomes and reduce toxicity ( mainly with intensive regimen), particularly in advanced-stage HL. In this context, the HD21 trial comparing BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), demonstrated lower toxicity, as well as improved 4-year progression-free survival (94.3% vs. 90.9%) and maintain overall survival (98.6% vs. 98.2%). The main treatment-related adverse events (AEs) include anemia, thrombocytopenia, neutropenia, and neuropathy, with dose reductions required due to AEs in 34% of patients treated with BEACOPP and 21% of those receiving BrECADD. These results suggest that the BrECADD combination may preserve or even improve therapeutic efficacy, while reducing the incidence of adverse events and, consequently, the need for dose modifications.

Aims: To describe the initial real-world data on the use of the BrECADD regimen for advanced-stage HL in Brazilian centers.

Methods: This is an observational, retrospective study conducted across six private Brazilian referral centers in Onco-Hematology. A total of 22 patients diagnosed and treated at these institutions between September 2023 and January 2026 were included.

Results: Among the 22 patients included, the first one was treated at sep/ 2023. Five had not yet completed the therapeutic protocol or realized final PET. The median age of the cohort was 36 years (range: 17–51 years), with 14 females and 8 males. Performance status was assessed using the Eastern Cooperative Oncology Group (ECOG) scale, with 100% of patients classified as ECOG 0 at treatment initiation. Regarding disease staging, most patients presented with advanced disease, with Ann Arbor stage IV observed in 68.2% (15 patients). The International Prognostic Score (IPS), 68.2% of patients had an IPS of 0–2, while 31.8% had an IPS ≥3. As preliminary results, 3/22 (13,63%) patients had iPET positive and realized 6 cycles of treatment. One of this patients had PET with Deauville 4 at the end of the treatment and was sent to radiotherapy ( now is waiting for final evaluation). No one patient had refractory disease or recidive (this is a very premature real life cohor